



# Source details

## Dermatology Reports

Open Access ⓘ

Scopus coverage years: from 2010 to Present

Publisher: PagePress

ISSN: 2036-7392 E-ISSN: 2036-7406

Subject area: Medicine: Dermatology

Source type: Journal

CiteScore 2021

0.9 ⓘ

SJR 2021

0.208 ⓘ

SNIP 2021

0.281 ⓘ

[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

### i Improved CiteScore methodology ⓘ

CiteScore 2021 counts the citations received in 2018-2021 to articles, reviews, conference papers, book chapters and data papers published in 2018-2021, and divides this by the number of publications published in 2018-2021. [Learn more >](#)

CiteScore 2021 ▾

$$0.9 = \frac{111 \text{ Citations 2018 - 2021}}{128 \text{ Documents 2018 - 2021}}$$

Calculated on 05 May, 2022

CiteScoreTracker 2022 ⓘ

$$0.9 = \frac{146 \text{ Citations to date}}{157 \text{ Documents to date}}$$

Last updated on 05 October, 2022 • Updated monthly

### CiteScore rank 2021 ⓘ

Category	Rank	Percentile
Medicine		
Dermatology	#91/126	28th

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site ↗](#)

## About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

## Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

## Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

---

## ELSEVIER

[Terms and conditions](#) ↗ [Privacy policy](#) ↗

Copyright © Elsevier B.V. ↗. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.





SJR

Scimago Journal & Country Rank

Enter Journal Title, ISSN or Publisher Name

Home

Journal Rankings

Country Rankings

Viz Tools

Help

About Us



### Advances in Civil Eng. Papers

Maximize the Impact, Reach & Visibility of Your Next Paper Publishing With Us

Hindawi

## Dermatology Reports

COUNTRY

Italy



Universities and research institutions in Italy

SUBJECT AREA AND CATEGORY

Medicine  
Dermatology

PUBLISHER

PagePress  
Publications

H-INDEX

12

PUBLICATION TYPE

Journals

ISSN

20367392, 20367406

COVERAGE

2010-2021

INFORMATION

[Homepage](#)

[How to publish in this journal](#)

[luigi.naldi@gised.it](mailto:luigi.naldi@gised.it)

### Journal Cover Letter Templates

Open

SCOPE



clinics of all skin-related diseases are welcome. Dermatology Reports publishes original articles, reviews, brief reports and case reports.

Join the conversation about this journal

## WA Blaster Anti Block dan Aman

WA Blaster Versi Paling Aman di Indonesia. Jaminan 99% Anti Ba Block.

Web Sender ID

Quartiles









## WA Blaster Anti Block dan Aman

WA Blaster Versi Paling Aman di Indonesia. Jaminan 99% Anti Ba Block.

Web Sender ID

### FIND SIMILAR JOURNALS ?

<p>1 <b>Indian Journal of Dermatology, Venereology</b> IND</p> <p><b>75%</b> similarity</p>	<p>2 <b>International Journal of Dermatology</b> GBR</p> <p><b>72%</b> similarity</p>	<p>3 <b>Dermatology Research and Practice</b> EGY</p> <p><b>69%</b> similarity</p>	<p>4 <b>Dermatologi</b> GBR</p> <p><b>6</b> s</p>
---	---	--	---



#### Dermatology Reports

Q3

Dermatology

best quartile

**SJR 2021**

0.21

powered by scimagojr.com

← Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimaç
```



Explore, visually communicate and make



---

## WA Blaster Anti Block dan Aman

WA Blaster Versi Paling Aman di Indonesia. Jaminan 99% Anti Ba Block.

Web Sender ID

---

Metrics based on Scopus® data as of April 2022

S **Samer Dhafer** 2 years ago

I'm proud to accept my article for publication in this highly esteemed journal..thanks to the editorial board. The process of evaluation and reviewing the manuscript was run in due time and the publication fee was reasonably affordable.

reply



**Melanie Ortiz** 2 years ago

SCImago Team

Dear Samer, thanks for your participation! Best Regards, SCImago Team

### Leave a comment

Name

Email

(will not be published)



Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2022. Data Source: Scopus®

EST MODUS IN REBUS  
Horatio (Satire 1,1,106)

Edit Cookie Consent



# Dermatology Reports



[ABOUT THE JOURNAL](#) [EDITORIAL BOARD](#) [CURRENT ISSUE](#) [ARCHIVES](#) [EARLY ACCESS](#)



## CASE OF THE MONTH / August 2022

### ***En coup de sabre morphea: An uncommon condition in Africa***

The term *en coup de sabre morphea* refers to a lesion of linear morphea typically located in the frontoparietal scalp and/or the paramedian forehead, often...

 <https://doi.org/10.4081/dr.2022.9537>





eISSN 2036-7406

EDITOR-IN-CHIEF

**Luigi Naldi**  
Italy

DERMATOPATHOLOGY



**Dermatology Reports**  
**Volume 11, No s1, 2019 - Special Issue**  
**for the 23<sup>rd</sup> Regional Conference of Dermatology (RCD)**  
***Surabaya, Indonesia - 8-11 August, 2018***



**PERDOSKI - INDONESIAN SOCIETY OF DERMATOLOGY AND VENEREOLOGY (INSDV)**



**IKATAN DOKTER INDONESIA (IDI)/INDONESIAN MEDICAL ASSOCIATION**



**DR. SOETOMO GENERAL HOSPITAL, UNIVERSITAS AIRLANGGA, INDONESIA**



## Special Issue for the 23<sup>rd</sup> Regional Conference of Dermatology (RCD) 2018 incorporating with the 16<sup>th</sup> Annual Scientific Meeting of the Indonesian Society of Dermatology and Venereology

### Table of Contents

#### ORIGINAL ARTICLES

<p><b>The role of protein-53 amyloid in determining the aggressiveness of basal cell carcinoma regulated by interleukin-6, myeloid cell leukemia-1 and basic fibroblast growth factor</b></p> <p>Prasetyadi Mawardi, Handono Kalim, Kusworini Handono Kalim, Loeki Enggar Fitri, Karyono Mintarjo, Ambar Mudigdo, Oyong Oyong, Brian Wasita.....1</p>	<p><b>Distribution of <i>Mycobacterium leprae</i> genotypes from Surabaya and Bandung Clinical Isolates by Multiple Locus Variable Number of Tandem Repeat Analysis</b></p> <p>Cita Rosita Sigit Prakoeswa, Bayu Bijaksana Rumondor, Lina Damayanti, Muljaningsih Sasmojo, Dinar Adriaty, Medhi Denisa Alinda, Ratna Wahyuni, M. Yulianto Listiawan, Indropo Agusni, Shinzo Izumi.....14</p>
<p><b>The efficacy of skin care products containing glutathione in delivering skin lightening in Indonesian women</b></p> <p>Kristiana Etnawati, Dwi Retno Adiwarni, Devi Artami Susetiati, Yusuke Sauchi, Hitomi Ito.....4</p>	<p><b>Potential for serodiagnosis of Indonesian leprosy patients by detecting antibodies against LID-1</b></p> <p>Nanny Herwanto, Sawitri, Cita Rosita Sigit Prakoeswa, Shinzo Izumi, Malcolm S. Duthie, Indropo Agusni .....19</p>
<p><b>Effect of country of origin image, product knowledge, brand familiarity to purchase intention Korean cosmetics with information seeking as a mediator variable: Indonesian women's perspective</b></p> <p>Emalia Diah Augusta, Dien Mardhiyah, Tika Widiastuti.....7</p>	<p><b>The role of beluntas (<i>pluchea indica</i> less.) leaf extract in preventing the occurrence of fibroblasts hyperproliferation: An <i>in vitro</i> preliminary study</b></p> <p>Sakti Charlia Maharani, Indah Julianto, Suci Widhiati .....22</p>
<p><b>Autologous non-cultured epidermal cell suspension combined with platelet rich fibrin for the treatment of stable vitiligo: A case series</b></p> <p>Adniana Nareswari, Dendy Zulfikar, Indah Julianto, Suci Widhiati .....11</p>	<p><b>Development of "Deskab" as an instrument to detect scabies for non-medical personnel in Indonesia</b></p> <p>Sandra Widaty, Roro Inge Ade Krisanti, Rahadi Rihatmadja, Eliza Miranda, Melani Marissa, Matahari Arsy, Danny Surya, Mufqi Priyanto, Sri Linuwih Menaldi.....25</p>

---

***Mycobacterium leprae* deoxyribonucleic acid positivity on skin lesion of untreated leprosy patients and its route to the skin surface**

Endi Novianto, Patricsia Manalu, Benny Effendi Wiryadi, Sri Linuwih Menaldi .....28

---

**Immunoglobulin AMG Anti Natural Disaccharide Octyl - Leprosy IDRI Diagnostic (NDO-LID) Serologic Test for Leprosy Diagnosis: A Pilot Study**

Bayu Bijaksana Rumondor, Anisha Callista Prakoeswa, Meva Nareza Trianita, Iswahyudi, Nanny Herwanto, M. Yulianto Listiawan, Indropo Agusni, Shinzo Izumi, Malcolm Duthie, Cita Rosita Sigit Prakoeswa .....31

---

**Comparison amount of microphthalmia-associated transcription factor in vitiligo before and after narrowband-ultraviolet B therapy**

M. Yulianto Listiawan, Linda Astari, Putri Hendria Wardhani .....35

---

**Comparison between fractional Co2 laser-triamcinolone injection combination therapy and triamcinolone injection monotherapy for keloid**

M. Yulianto Listiawan, Dwi Murtiastutik, Willy Sandhika, Brama Rachmantyo, Putri Hendria Wardhani .....38

---

**Why are they hard to treat? A preliminary survey to predict important factors causing persistent scabies among students of religion-affiliated boarding schools in Indonesia**

Rahadi Rihatmadja, Eliza Miranda, Melani Marissa Wicaksono, Sandra Widaty .....41

---

**The relationship between skin phototype, gender, and stress level with the incidence of acne vulgaris among adolescents in Surakarta**

Ardian Hendra Rezi Pamungkas, Flora Ramona Sigit Prakoeswa .....44

---

**The efficacy and safety of fractional erbium yag laser combined with topical amniotic membrane stem cell (AMSC) metabolite product for facial rejuvenation: A controlled, split-face study**

Ni Putu Susari Widianingsih, Trisniartami Setyaningrum, Cita Rosita S. Prakoeswa .....48

---

**Sleep problems in 0-36 months old Indonesian children with atopic dermatitis**

Irwanto, Hapsari W. Ningtiar, Taufiq Hidayat, Azwin M. Putera, Zahrah Hikmah, Anang Endaryanto .....53

---

**A comparative study of Chicago Sky Blue and Parker™ ink blue black potassium hydroxide in the diagnosis of dermatophytes**

Netty Sukmawati, Rahmadewi, Evy Ervianti .....56

---

**Detection of *ureaplasma urealyticum* by polymerase chain reaction examination in nonspecific genital infection patients**

Rahmadewi, Dian PH .....59

---

**Profile of patients with tinea capitis**

Siti Amira Venitarani, Samsriyaningsih Handayani, Evy Ervianti .....62

---

**The effect of combination narrowband ultraviolet B phototherapy and vitamin D3 supplementation to increase serum 25-(OH)D levels in adult vitiligo patients**

Reiva Farah Dwiwana, Fatima Aulia Khairani, Pufana Meidelia, Unwati Sugiri, Reti Hindritiani, Hendra Gunawan, Oki Suwarsa .....65

---

**Is leukotriene B4 one of the keloid marker? A fibroblast keloid study**

Yuli Kurniawati, Oki Suwarsa, Achadiyani, Sudigdo Adi .....68

---

**Predictor factor of inguinal lymph node metastasis in men with penile cancer at Sanglah General Hospital, Denpasar, Bali**

I. Wayan Yudiana, Gede Wirya Kusuma Duarsa, Anak Agung Gde Oka, Kadek Budi Santosa, Pande Wisnu Tirtayasa, Harmaya AK, Wahjoe Djatisoesanto .....71

---

**Reading the history of venereal diseases in the city: Venereal disease from Surabaya, 19th-20th century**

Moordiati .....75

---

**A simpler diagnostic method using blood collection on filter paper to determine anti-natural octyl disaccharide-leprosy infectious disease research institute diagnostic in household contacts of leprosy patients**

Meva Nareza Trianita, Bayu Bijaksana Rumondor, Anisha Callista Prakoeswa, Iswahyudi, Dinar Adriaty, Bagus Haryo Kusumaputra, Muhamad Yulianto Listiawan, Indropo Agusni, Shinzo Izumi, Malcolm Duthie .....78

---

**The efficacy of vitamin D3 supplementation in increasing 25-hydroxyvitamin D levels in childhood vitiligo patients receiving 308-nm-excimer light phototherapy**

Reiva Farah Dwiayana, Pramita K.C. Nugrahaini, D.P. Larasati, Inne Arline Diana, Reti Hindritiani, Hendra Gunawan, Oki Suwarsa .....81

---

**Nongonococcal cervicitis: The most common cause of fluor albus in female sex workers**

Afif Nurul Hidayati, Astindari, Maylita Sari, Dwi Murtiastutik, Sunarko Martodihardjo, Jusuf Barakbah .....84

---

**Is insulin topical gel better than simvastatin topical gel in full thickness wound?**

Timotius Hansen Arista, Agus Santoso Budi, Mirnasari Amirsyah, Nanda Febry Setyawati .....87

---

**Causative drugs and HLA-B polymorphism in drug-induced Stevens-Johnson syndrome - toxic epidermal necrolysis: A study in five hospitals in Jakarta**

Anesia Tania, Evita Halim Effendi, Inge Ade Krisanti, Yulia Ariani .....90

---

**Hematological, hepatic, and renal adverse effects of high dose methotrexate injection (50 mg weekly) in severe psoriasis cases**

Adissa Tiara Yulinvia, Prasta Bayu Putra, Niken Trisnowati, Sunardi Radiono .....93

---

**The relationship between human leukocyte antigen-cw6 allele and psoriasis vulgaris**

Sri Lestari KS, Eryati Darwin, Tjut Nurul Alam Jacob, Djong Hon Tjong .....96

---

**Polymerase chain reaction chlamydia trachomatis examination in nonspecific genital infection patients**

Dian Pertiwi Habibie, Dwi Murtiastutik, Rahmadewi .....100

---

**Ph value of infant's skin is higher on diaper area compared to nondiaper area**

Nadia Wirantari, Linda Astari, Iskandar Zulkarnain .....103

---

**The Correlation of Ig M Anti PGL-1 Antibody between Blood Veins and Dried Capillary Blood on Filter Papers in Household Contact of Leprosy Patient**

Anisha Calista Prakoeswa, Bayu Bijaksana Rumondor, Meva Nareza Trianita, Iswahyudi, Fatma Rosida, Linda Astari, M. Yulianto Listiawan, Indropo Agusni, Shinzo Izumi, Medhi Denisa Alinda .....106

---

**Staphylococcus aureus colonization on antecubital non-exacerbated atopic dermatitis patient compared to healthy children**

Nur Khamidah, Evy Ervianti, Hari Sukanto .....109

---

**Cutaneous adverse drug reaction in Human Immunodeficiency virus patient associated with antiviral therapy: A retrospective study**

Vidyani Adiningtyas, Cita Rosita Sigit Prakoeswa, Erwin Astha Triyono .....112

---

**Neisseria gonorrhoeae resistance test against cefixime in gonorrhea patients in Surabaya**

Amalia Rositawati, Sawitri, Afif Nurul Hidayati .....115

---

**Urinary leukotriene e4 level profile in various degrees of severity in atopic dermatitis patients in dermatovenereology outpatient clinic Dr. Soetomo General Hospital, Surabaya: A descriptive study**

Meita Ardini Pratamasari, M. Marsoedi Hoetomo, Afif Nurul Hidayati .....119

---

**Genotyping of Human Papilloma Virus (HPV) in female condyloma acuminata patient in Dr. Soetomo Hospital, Surabaya**

Afria Arista, Dwi Murtiastutik, Trisniartami Setyaningrum, Gondo Mastutik .....122

---

**Profile of antiretroviral and its outcome on patients with HIV-AIDS in Wamena Public Hospital**

Erwin Astha Triyono, Stefania Rany Seran, Didik Hasmono .....124

---

**Urinary melatonin levels in children with atopic dermatitis and healthy controls**

Dwi Ratna Adisty, Iskandar Zulkarnain, Diah Mira Indramaya .....129

## CASE REPORTS

---

### **Importance of dermoscopy in diagnosis of tinea capitis: An evidence-based case report**

Aninda Marina, Marsha Bianti, Sandra Widaty,  
Eliza Miranda .....131

---

### **Fractional laser and laser assisted corticosteroid delivery for hypertrophic scars in thermal burns**

Ni Putu Susari Widianingsih,  
Cita Rosita S. Prakoeswa .....134

---

### **Mini punch graft for chronic leg ulcers, case series**

Angela Mistralina Lukito,  
Dinda Saraswati Murniastuti, Hajar Imtihani,  
Niken Trisnowati,  
Yohanes Widodo Wirohadidjojo.....136

---

### **The application of liposomal azelaic acid, 4-n butyl resorcinol and retinol serum enhanced by microneedling for treatment of malar pattern melasma: A case series**

Arie Kusumawardani, Anggana Rafika Paramitasari,  
Susanti Rosmala Dewi,  
Ance Imelda Betaubun .....139

---

### **Hair removal treatment using 1,064 nm long-pulsed Nd:YAG laser in auricular post reconstruction of microtia patient: Two case reports**

Kartika Ruchiatan, Erika Dewi Essary,  
Reti Hindritiani, RM Rendy Ariezal Effendi,  
Rani Septrina, Hendra Gunawan,  
Oki Suwarsa.....142

---

### **Slow responder against methotrexate 50 mg intramuscular in severe psoriatic patients: A case series**

Niken Kusumaningrum, Danar Wicaksono,  
Dwi Retno Adi Winarni, Yohanes Widodo  
Wirohadidjojo, Sunardi Radiono.....145

---

### **Subcutaneous phaeohyphomycosis: A rare case**

Zahrudin Ahmad, Diah Mira Indramaya,  
Yuri Widia, Sylvia Anggraeni, Linda Astari,  
Evy Ervianti, Sunarso Suyoso .....149

---

### **Xeroderma pigmentosum with ocular involvement and squamous cell carcinoma: A case report**

Bernadya Yogatri Anjuwita Saputri,  
Iskandar Zulkarnain.....153

---

### **Scabies incognito**

Nanny Herwanto, Hasnikmah Mappamasing,  
Septiana Widiyanti, Trisiswati Indranarum,  
Afif Nurul Hidayati, Sawitri, Evy Ervianti,  
Dwi Murtiastutik, Sunarko Martodihardjo.....157

---

### **Decompression and gutter splint techniques to prevent recurrence in ingrowing toenails**

Eva Krishna Sutedja, Vina Feriza,  
Rachel Marsella Rahardjo, Dina Fatmasari,  
Reti Hindritiani, Hendra Gunawan,  
Oki Suwarsa.....160

---

### **Crusted scabies in systemic lupus erythematosus: More than a mite contagious case**

Eva Lydiawati, Indropo Agusni, Dwi Murtiastutik,  
Evy Ervianti, Sawitri, Trisiswati Indranarum,  
Septiana Widyantari,  
Hasnikmah Mappamasing .....163

---

### ***Aspergillus fumigatus* as an agent of cutaneous aspergillosis in immunocompetent patient: A rare case**

Trisniartami Setyaningrum,  
Karina Dyahtantri Pratiwi .....166

---

### **A split-face of dermaroller and intradermal injection with the autologous platelet rich fibrin lysate in the treatment of exogenous ochronosis: A case series**

Moerbono Mochtar, Sri Esa Ilona, Dendi Zulfikar,  
Ammarilis Murastami, Suci Widhiati .....169

---

### **Dermoscopic evaluation of tinea capitis: A case report**

Ade Fernandes, Yuri Widia, Sylvia Anggraeni,  
Linda Astari, Evy Ervianti, Sunarso Suyoso.....173

---

### **Establishing the diagnosis neurofibromatosis type 1: A rare case**

Dyatiara Devy, Damayanti .....176

---

### **A rare case report: Acquired vulva lymphangioma in a young female post tubercular lymphadenitis**

Marissa Astari, Afif Nurul Hidayati .....178

---

**Diffuse lepromatous leprosy caused by dual infection of mycobacterium leprae and mycobacterium lepromatosis: A case report**

Ridha Ramadina Widiatma, Hari Sukanto .....180

---

**Crusted scabies in patients with long-term use of oral corticosteroid with different underlying diseases – case series**

Cut Shelma Maharani, Densy Violina Harnanti, Hasnikmah Mappamasing, Septiana Widyantari, Sawitri, Evy Ervianty, Dwi Murtiastutik, Sunarko Martodihardjo, M. Yulianto Listiawan .....183

---

**Successful treatment of severe psoriasis vulgaris in child with methotrexate injection**

Agatha Anindhita, Sawitri .....186

---

**Serial case reports: Pregnancy with Lucio's phenomenon of leprosy in dr. Soetomo hospital, Surabaya**

Nareswari I. Cininta, M.I.A. Akbar, Rozi A. Aryananda, Khanisyah E. Gumilar, Manggala Pascawardhana, Budi Wicaksono, Ernawati, Agus Sulistyono, Aditiawarman, Hermanto T. Joewono, M.N. Abdullah, Erry G. Dachlan .....189



# Dermatology Reports



[ABOUT THE JOURNAL](#) [EDITORIAL BOARD](#) [CURRENT ISSUE](#) [ARCHIVES](#) [EARLY ACCESS](#)

[HOME](#) / [Editorial Board](#)

## Editorial Board

### Editor-in-Chief

Luigi Naldi (Vicenza, Italy)  
[luigi.naldi@gised.it](mailto:luigi.naldi@gised.it)

### Associate Editors

Cesare Massone (Genova, Italy)  
[cesare.massone@gmail.com](mailto:cesare.massone@gmail.com)

Francesca Sampogna (Roma, Italy)  
[fg.sampogna@gmail.com](mailto:fg.sampogna@gmail.com)

### SIDCO Deputy Editors

Giulio Gualdi (Chieti, Italy)  
[giulioqualdi@libero.it](mailto:giulioqualdi@libero.it)

## **Section Editors**

### ***Case Reports***

Paolo Sena (Bergamo, Italy)

Bruno Sassolas (Brest, France)

### ***Dermatopathology***

Gerardo Ferrara (Macerata, Italy)

Jean Kanitakis (Lyon, France)

### ***Clinical Reviews***

Carlo Cota (Ancona, Italy)

Ignacio García Doval (Vigo, Spain)

### ***Procedural Dermatology and Dermatosurgery***

Pier Luca Bencini (Milano, Italy)

Davide Melandri (Cesena, Italy)

Massimo Gattoni (Vercelli, Italy)

### ***Imaging in dermatology***

Enzo Errichetti (Udine, Italy)

### ***Epidemiology/Clinical Research***

Damiano Abeni (Roma, Italy)

Dennis Linder (Venezia, Italy)

### ***Pediatric Dermatology***

May El Hachem (Roma, Italy)

Andrea Sechi (Vicenza, Italy)

### ***Cutaneous appendages***

Vincenzo Bettoli (Ferrara, Italy)

Elena Pezzolo (Vicenza, Italy)

### ***Melanoma and Dermato-Oncology***

Ignazio Stanganelli (Meldola/FC, Italy)

Fabrizio Fantini (Lecco, Italy)

### ***Psychodermatology***

Anna Burroni (Genova, Italy)

### ***Patient corner***

Eugenia Caggese (Bergamo, Italy)

Giuseppe Formato (Campobasso, Italy)  
Visnja Zaborski Breton (Ottawa, Canada)

### **Nursing**

Daniela Ferrari (Vicenza, Italy)

### **Statistical advisor**

Simone Cazzaniga (Bergamo, Italy)

## **Editorial Advisory Board**

Lucia Brambilla (Milano, Italy)  
Antonio Cristaudo (Roma, Italy)  
Giuseppe Cianchini (Roma, Italy)  
Anna Di Landro (Bergamo, Italy)  
Ornella De Pità (Roma, Italy)  
Luca Fania (Roma, Italy)  
Michele Fimiani (Siena, Italy)  
Giovanni Ghigliotti (Genova, Italy)  
Giovanna Malara (Reggio Calabria, Italy)  
Aldo Morrone (Roma, Italy)  
Michele Pellegrino (Grosseto, Italy)  
Francesca Romano (Napoli, Italy)  
Michela Venturi (Cesena, Italy)  
Vito Ingordo (Taranto, Italy)

## **ADOI Board of Directors**

Francesco Cusano *President* (Benevento, Italy)  
Cesare Massone *Vice-president* (Genova, Italy)  
Leonardo Bianchi (Perugia, Italy)  
Luca Fanà (Roma, Italy)  
Giovanna Galdo (Avellino, Italy)  
Paolo Iacovelli (Roma, Italy)  
Davide Melandri (Cesena, Italy)  
Michele Pellegrino (Grosseto, Italy)  
Riccardo Sirna (Grosseto, Italy)

## IMI Board of Directors

Ignazio Stanganelli (president) (Meldola/FC, Italy)  
Daniela Massi (Firenze, Italy)  
Pietro Quaglino (Torino, Italy)  
Corrado Caracò (Napoli, Italy)  
Virginia Ferraresi (Roma, Italy)  
Antonio M. Grimaldi (Napoli, Italy)  
Roberto Patuzzo (Milano, Italy)  
Giuseppe Palmieri (Sassari, Italy)  
Mario Mandalà (Bergamo, Italy)  
Paola Queirolo (Milan, Italy)  
Stefania Stucci (Bari, Italy)

## SIDCO Board of Directors

Marco Dal Canton (President)  
Gian Marco Vezzoni (Incoming President),  
Marco Simonacci (Past President)  
Maurizio Lombardo (Treasurer)  
Fabrizio Fantini (Advisor, SIDCO ADOI Contact Person)  
Andrea Paradisi (Advisor)  
Paolo Sbanò (Advisor)  
Malvina Zanchi (Secretary)

### FOR AUTHORS

#### SUBMIT YOUR PAPER

---

[Guide for Authors](#)

---

[Benefits for Authors](#)

---

[How to write a scientific paper](#)

---

[How to write a Review article](#)

---

[Article Processing Charge](#)

---

[Crediti ECM \(Italian Authors\)](#)

## Comparison amount of microphthalmia-associated transcription factor in vitiligo before and after narrowband-ultraviolet B therapy

M. Yulianto Listiawan, Linda Astari, Putri Hendria Wardhani

Department of Dermatology and Venereology, Faculty of Medicine, Airlangga University, Dr. Soetomo General Hospital, Surabaya, Indonesia

### Abstract

Vitiligo is the most commonly seen depigmentation disease with clinical manifestations of milk colored white macules, complex pathogenesis that is not well understood so that evolution of the disease is unpredictable and therapeutic outcomes are often unsatisfactory. Until now narrowband-ultraviolet B (NB-UVB) is considered the most effective and safe treatment for vitiligo. Therapy evaluation by looking at melanocytes function that can be seen with microphthalmia-associated transcription factor (MITF) immunohistochemistry will become more objective and accurate. This is a comparative analytic experimental study using pre-post test method comparing MITF in vitiligo patients before and after receiving NB-UVB conducted at Dr. Soetomo general hospital Surabaya, 12 vitiligo samples treated only with NB-UVB twice a week until 8 times therapies. The first exposure dose was 200 mJ and gradually increased 20% every therapy. Biopsy was performed before and after therapies and then MITF was compared. There was a significant difference between the amount of MITF in vitiligo before NB-UVB and after NB-UVB therapy statistically,  $p < 0.001$  ( $p = 0.05$ ). MITF is useful for indicators of treatment success.

### Introduction

Vitiligo is the most commonly seen depigmentation disease with clinical manifestations of milk colored white macules. Vitiligo is an acquired disease with complex pathogenesis that is not well understood so that the evolution of the disease is unpredictable and the outcome of therapy is often unsatisfactory. This leads to a decrease in

quality of life, anxiety, lack of confidence in establishing a relationship, and psychosocial stigma in vitiligo patients.<sup>1,2</sup> Vitiligo accounts for 0.3-0.5% of the world's population. The prevalence of vitiligo has shown an increase over the past few decades.<sup>1,3</sup>

Vitiligo is a multifactorial, polygenic disease, from many theories of disease pathogenesis, the most accepted is the interaction of genetic and nongenetic factors to affect the function and survival of melanocytes.<sup>1</sup> The earliest formation of melanocytes is regulated by Microphthalmia-Associated Transcription Factor (MITF), a main gene for survival of melanocytes and key regulatory factors of melanogenic protein transcription.<sup>4</sup> MITF is a new melanocytic marker that allows estimation of the number of melanocytes within the epidermis and to detect function deterioration, MITF is more accurate and the easiest to interpret because of clean core expression and minimal disturbance of pigments melanin cytoplasm, the best immunohistochemical marker for epidermal melanocytes.<sup>5-7</sup> In Bastonini's study, 2015 reported a deficiency of MITF expression on the edge of vitiligo lesions that contribute to the change and loss of melanocytes.<sup>8</sup>

The principle of vitiligo therapy is to facilitate the repopulation of depigmented patches with active melanocytes that can migrate, and perform the biosynthesis of melanin. Until now Narrowband UVB (NB-UVB) is considered to be the most effective and safe for vitiligo therapy.<sup>1</sup> Clinicians evaluate the results of vitiligo therapy only with clinical repigmentation percentage.<sup>1,4</sup> Understanding of repigmentation until now is not even yet, only subjectively. The objective evaluation of repigmentation is important for clinicians as an indicator of success or failure of therapy. Evaluation of therapy by looking at the function and the amount of melanocytes will become more objective and accurate.

In this study will be evaluated the amount of MITF in vitiligo patient lesions prior to NB-UVB therapy compared with after NB-UVB therapy. By proving the role of MITF n by looking at increasing the number of MITF in vitiligo after NB-UVB therapy, it can be an indicator of the efficacy of vitiligo therapy.

### Materials and Methods

A study was conducted on 24 samples consisting of 12 pre-test samples and 12 post-test samples. All samples meet sample

Correspondence: Putri Hendria Wardhani, Department of Dermatology and Venereology, Faculty of Medicine, Airlangga University, Dr. Soetomo General Hospital, Surabaya, Indonesia.  
Tel: +62315501609  
E-mail: putri\_h\_w@yahoo.com

Key words: MITF, NB-UVB, Vitiligo

Contributions: All the authors contributed equally.

Conflict of interest: the authors report no conflict of interest.

Received for publication: 1 February 2019.  
Accepted for publication: 11 February 2019.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

©Copyright M.Y. Listiawan et al., 2019  
Licensee PAGEPress, Italy  
Dermatology Reports 2019; 11(s1):8030  
doi:10.4081/dr.2019.8030

requirements and are willing to participate in the research by signing information for consent, informed consent and medical action approval sheets. The research was conducted from May 2017 until August 2017 at Outpatient Clinic, Dr. Soetomo general hospital Surabaya. Each sample was recorded and 3 mm biopsy biopsy was performed, and MITF immunohistochemistry were performed to calculate the amount of MITF in two fields of view, one view per millimeter.

### Results

We did the normality test to know the distribution of data in this study. This study used the Shapiro-Wilk parameter because the total number of patients was less than 50. From the Shapiro-Wilk parameter, the difference in the amount of MITF in vitiligo before and after NB therapy -UVB was normally distributed distribution ( $p = 0.024$ ), ( $p > 0.05$ ). Normally distributed variables use paired t test (Table 1).

With paired t test, p value = 0.000 ( $p < 0.05$ ). In interpreting the data, the p value is reported as  $p < 0.001$  to prevent multiple interpretations because the p value = 0.000 does not mean pure zero value. Statistically, it was found that there was a significant difference between the amount of MITF in vitiligo before NB-UVB and vitiligo therapy after NB-UVB therapy as




Figure 1. MITF before NB-UVB therapy.




Figure 2. MITF after NB-UVB therapy.

Table 1. Normality Test.

	Statistic	Shapiro-Wilk df	Sig.
Difference in the amount of MITF in vitiligo before and after NB therapy -UVB	.948	12	.612

Table 2. Paired t test.

	Mean (s.d)	Difference (s.d)	CI95%	p
The amount of MITF in vitiligo prior to NB-UVB therapy (n=12)	2,5 (2,28)	7,92 (4,44)	5,09-10,74	<0,001
The amount of MITF in vitiligo after NB-UVB therapy (n=12)	10,42 (3,63)			

measured by MITF painting in 2 field of view,  $p < 0.001$  ( $p = 0.05$ ) (Table 2).

## Discussion

In vitiligo before the treatment of NB-UVB (Figure 1) obtained at most four melanocyte cells per one millimeter field of view and not rarely found no melanocyte in one field of view. In the two most visible fields found eight melanocytes, and two patients had no melanocytes at all. In vitiligo after NB-UVB therapy (Figure 2) there were at most sixteen melanocytes in two field of view and at least five melanocytes. In one field of vision there were found to be nine melanocytes, and at least two melanocytes in one field.

Statistically, it was found that there was a significant difference between the amount of MITF in vitiligo before and after NB-UVB therapy as measured by MITF paint-

ing in 2 field of view,  $p < 0.001$  ( $p = 0.05$ ). This proves that MITF can be used to monitor the evaluation of vitiligo therapy.

Vitiligo is a depigmentation disorder characterized by loss of melanocyte function in the epidermal, multifactorial and pathogenic causes that overlap one another. Many studies have proven that morphological and functional melanocyte abnormalities exist. Previous research has proposed a mechanism involving MITF, a transcriptional factor that controls the melanin synthesis pathway. UV can induce the activation of transcription factors, one of which is important is MITF, a gene that acts to synthesize melanin found in melanosomes and is exported to keratinocytes.<sup>9,10</sup> This is in line with the results of this study that an increase in the amount of MITF after NB-UVB therapy was compared before NB-UVB therapy, so it can be concluded MITF has a role as an objective evaluation of vitiligo therapy.

## Conclusions

Increasing number of MITF in vitiligo patients after receiving NB-UVB therapy than before NB-UVB therapy is statistically different significantly. This suggests MITF has a role as an indicator of the success of vitiligo therapy.

## References

1. Birlea SA, Spritz RA, Norris DA. Vitiligo. Dalam: Wolff K, Goldsmith LA, Katz SI, Gilchrist BA, Leffel DJ, editors. Fitzpatrick's Dermatology General Medicine. 8th Ed. New York: McGraw Hill Co; 2013. pp 792-803.
2. Kutlubay Z, Karakus O, Engin B, Serdaroglu S. Vitiligo as autoimun disease. J Turk Acad Dermatol 2012;6: 126r1.
3. Alikhan MD, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: A comprehensive overview. J Am Acad Dermatol 2011;65:473-91.
4. Park HY, Yaar M. Biology of melanocytes. Dalam: Wolff K, Goldsmith LA, Katz SI, Gilchrist BA, Leffel DJ, editors. Fitzpatrick's Dermatology in General Medicine 8th Ed. New York: McGraw Hill Co; 2013. pp 792-803.
5. Prieto VG, Shea CR. Immunohistochemistry of melanocytic proliferations. Arch Pathol Lab Med 2011;135:853-9.
6. Sheffield MV, Yee H, Dorvault CC, et al. Comparison of Five Antibodies as

markers in the diagnosis of melanoma in cytologic preparations. *Am J Clin Pathol* 2002;118:930-6.

7. Nybakken GE, Sargen M, Abraham R, et al. MITF accurately highlight epidermal melanocytes in atypical intraepidermal melanocytic proliferations. *Am J Dermatopathol* 2013;35(1):25-9.
8. Bastonini E, Kovacs D, Picardo M. Skin pigmentation and pigmentary disorders: focus on epidermal/ dermal cross-talk. *Ann Dermatol* 2016;28:279-89.
9. Lee CH, Wu SB, Hong CH, Yu HS, Wei YH. Molecular mechanisms of UV-induced apoptosis and its effects on skin residential cells: the implication in UV-based phototherapy. *Int J Mol Sci* 2013;14:6414-35.
10. Videira IFS, Magina S, Moura DFL. Mechanisms regulating melanogenesis. *An Bras Dermatol* 2013;88:76-83.

Non-commercial use only